Who is sponsoring NCT06582940?

NCT06582940 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06582940?

Interventions in NCT06582940: MRI-guided adaptive SRT, Conventional SRT.

What condition does NCT06582940 study?

NCT06582940 studies MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis.

Is NCT06582940 still recruiting?

NCT06582940 is currently recruiting now. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT06582940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis

Recruiting now Phase 2 Last updated 17 November 2025

What this trial tests

Phase 2 trial testing MRI-guided adaptive SRT in MRI-guided Adaptive Radiotherapy in 168 participants. Currently enrolling.

Timeline

1 March 2024

Primary endpoint
1 March 2026

1 March 2026

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	168
Start date	1 March 2024
Primary completion	1 March 2026
Estimated completion	1 March 2026
Sites	1 location across China

Drugs / interventions tested

MRI-guided adaptive SRT
Conventional SRT

Conditions studied

MRI-guided Adaptive Radiotherapy — all drugs for MRI-guided Adaptive Radiotherapy →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Brain Metastasis — all drugs for Brain Metastasis →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with MRI-guided Adaptive Radiotherapy or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06582940 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06582940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing